HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Stock Information for HOOKIPA Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About HOOKIPA Pharma Inc.

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.